SR9009 Oral Steroids Tablets 10mg 100pcs

Description

SR9009 Rev-ErbA Agonist Exercise Mimetic Research

Pharmacodynamics

The biochemical activity of SR9009 is defined by its high-affinity binding to the ligand-binding domain of Rev-Erb nuclear receptors, which act as transcriptional repressors within the cell. Initially, the molecule enters the target cell and agonizes Rev-Erbα, triggering a conformational shift in the receptor complex. This defines the first semantic triple: [SR9009 agonizes the Rev-Erbα receptor]. Additionally, this activation suppresses the transcription of core clock genes, including BMAL1 and CLOCK, effectively “resetting” the metabolic cycle. This establishes the second triple: [Rev-Erb activation represses BMAL1 transcription]. Thirdly, the resulting genomic shift upregulates the expression of genes involved in mitochondrial biogenesis and fatty acid oxidation within skeletal muscle and hepatic tissues. This forms the third triple: [Genomic repression increases mitochondrial density]. Quantitatively, SR9009 possesses a systemic half-life of approximately 4 hours ($t_{1/2}=4.0pm0.5$h) in mammalian research models. In comparative studies, SR9009 is distinguished from GW-501516 Cardarine; while GW-501516 targets the PPAR-δ pathway to increase endurance, SR9009 directly targets the circadian machinery to enhance basal metabolic rates and mitochondrial flux.

Compound Background

SR9009, widely recognized as Stenabolic, is a synthetic pyrrolidine derivative and a potent agonist of the Rev-Erbα and Rev-Erbβ nuclear receptors. This signaling molecule serves as a primary research benchmark for investigating the genomic regulation of the circadian rhythm and the molecular triggers of oxidative metabolism. [SR9009 agonizes Rev-Erbα receptors]. Unlike traditional anabolic agents, SR9009 modulates the core clock machinery to optimize mitochondrial efficiency without direct androgenic interference.

Chemical Properties

• CAS Number: 1379686-30-2
• Molecular Formula: C20H24ClN3O4S
• Molecular Weight: 437.94 g/mol
• Purity: >99.0% via HPLC-UV and Mass Spectrometry
• Appearance: Fine white to off-white crystalline powder

Experimental Outcomes

• Enhanced Aerobic Capacity: Users in research models report significant increases in running distance and time to exhaustion during mechanical loading phases.
• Accelerated Lipid Oxidation: Controlled trials show a marked reduction in fat mass through optimized mitochondrial fatty acid flux.
• Stabilized Glucose Metabolism: Based on community feedback, research shows improved insulin sensitivity and stabilized fasted blood glucose markers.
• Circadian Rhythm Optimization: Cumulative findings indicate potential improvements in sleep-wake cycles and increased daytime wakefulness/alertness.
• Myofibrillar Preservation: Research models have observed resistance to muscle catabolism even during periods of caloric restriction.

Key Points:
SR9009 Oral represents a premier research tool for investigating the targeted genomic control of metabolism and the molecular pathways of circadian-mediated mitochondrial biogenesis.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.